IDEXX Laboratories, Inc. $IDXX Shares Bought by California Public Employees Retirement System

California Public Employees Retirement System grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.2% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 157,570 shares of the company’s stock after purchasing an additional 9,162 shares during the period. California Public Employees Retirement System’s holdings in IDEXX Laboratories were worth $100,670,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $30,000. J.Safra Asset Management Corp acquired a new position in IDEXX Laboratories in the third quarter valued at approximately $31,000. Armstrong Advisory Group Inc. grew its position in IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after acquiring an additional 19 shares during the period. Salomon & Ludwin LLC acquired a new stake in IDEXX Laboratories during the third quarter worth $35,000. Finally, Greykasell Wealth Strategies Inc. acquired a new stake in IDEXX Laboratories during the third quarter worth $35,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president owned 9,823 shares in the company, valued at approximately $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Sophie V. Vandebroek sold 1,464 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the transaction, the director directly owned 648 shares in the company, valued at $407,345.76. This trade represents a 69.32% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 45,957 shares of company stock worth $29,862,109. 0.98% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Barclays cut their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. UBS Group reduced their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Weiss Ratings cut shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Finally, Piper Sandler lowered their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

IDEXX Laboratories Stock Up 2.2%

Shares of NASDAQ:IDXX opened at $586.37 on Tuesday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The firm’s 50 day moving average price is $656.25 and its 200 day moving average price is $666.45. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The stock has a market cap of $46.69 billion, a price-to-earnings ratio of 44.86, a price-to-earnings-growth ratio of 3.48 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the firm earned $2.53 EPS. The company’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.